Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S, Shim MK, Kim WJ, Choi J, Nam GH, Kim J, Kim J, Moon Y, Kim HY, Park J, Park Y, Kim IS, Ryu JH, Kim K.
Yang S, et al. Among authors: kim hy, kim wj, kim is, kim j, kim k.
Biomaterials. 2021 May;272:120791. doi: 10.1016/j.biomaterials.2021.120791. Epub 2021 Apr 1.
Biomaterials. 2021.
PMID: 33831739